1. Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory Confirmed SARS-CoV-2 Infection Based on Pregnancy Status – United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1641–1647.
2. De Sisto CL, Wallace B, Simeone RM, et al. Risk of stillbirth among women with and without COVID-19 at hospitalization for childbirth – United States, March 2020-September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1640–1645.
3. Ass AA, Chemaitelly H, Al Khal A, et al. Efficacy of the SARS-CoV-2 vaccine in the prevention of confirmed infection in pregnant women. JClin Invest 2021; 131 (23):and153662–and153662.
4. Dagan N, Barda N, Biron-Shental T, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med 2021; 27:1693–1695
5. Lipkind HS, Vazquez-Benitez G, De Silva M, et al. Receiving COVID-19 Vaccine During Pregnancy and Preterm or Gestational Age at Birth – Eight Integrated Health Organizations, United States, December 15, 2020 – July 22, 2021. MMWR Morb Mortal Wkly Rep 2022; 71:26–30.
6. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings on the safety of Covid-19 mRNA vaccine in pregnant people. N English J Med 2021; 384:2273–2282.
7. Zauch LH, Wallace B, Smooth AN, et al. Reception of Covid-19 mRNA vaccines and risk of miscarriage. N English J Med 2021; 385:1533–1535.
8. Magnus MC, Gjessing HK, Eide HN, Wilcox AJ, Fallen DB, Haberg SE. Covid-19 Vaccination in pregnancy and spontaneous abortion in the first trimester. N English J Med 2021; 385:2008–2010.
9. Centers for Disease Control and Prevention. COVID-19 vaccines during pregnancy or breastfeeding (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html).
10. Abu Raya B, Edwards KM, Scheifele DW, Halperin SA. Immunization Against Pertussis and Influenza During Pregnancy: A Landscape Review. Lancet Infect Dis 2017; 17 (7):and209–and222.
11. Aziz-Baumgartner E, Grohskopf L, Patel M. Realize the potential of maternal flu vaccination. JAMA 2021; 325:2257–2259.
12. Omer SB. Maternal immunization. N English J Med 2017; 376:1256–1267.
13. Halasa NB, Olson SM, Staat MA, et al. Efficacy of maternal vaccination with COVID-19 mRNA vaccine during pregnancy against COVID-19 associated hospitalization in infants less than 6 months of age – 17 states, July 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:264–270.
14. Carlsen EØ, Magnus MC, Oakley L, et al. Association of COVID-19 vaccination during pregnancy with the incidence of SARS-CoV-2 infection in newborns. JAMA Intern Med 2022 June 1 (Epub before print).
15. Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Umbilical cord blood antibodies after maternal coronavirus vaccination 2019 during pregnancy. Am J Obstet Gynecol 2021; 225:192–194.
16. Beharier O, Plitman Mayo R, Raz T, et al. Efficient maternal-neonatal transfer of antibodies to the SARS-CoV-2 vaccine and BNT162b2 mRNA COVID-19. JClin Invest 2021; 131:150319–150319.
17. Prabhu M, Murphy EA, Sukhu AC, et al. Antibody response to coronavirus disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into umbilical cord blood. Ostet Gynecol 2021; 138:278–280.
18. Perl SH, Uzan-Yulzari A, Klainer H, et al. Specific antibodies to SARS-CoV-2 in breast milk after COVID-19 vaccination of breastfeeding women. JAMA 2021; 325:2013–2014.
19. Baird JK, Jensen SM, Urba WJ, Fox BA, Baird JR. SARS-CoV-2 antibodies detected in breast milk after vaccination. J Hum Lact 2021; 37:492–498.
20. Yang YJ, Murphy EA, Singh S, et al. Association of gestational age with coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a booster dose of the vaccine with cord antibody levels umbilical and maternal at the time of childbirth. Ostet Gynecol 2022; 139:373–380.
21. Trostle ME, Aguero-Rosenfeld ME, Romano AS, JL lighter. High levels of antibodies in the umbilical cord blood of pregnant women vaccinated against COVID-19. Am J Obstet Gynecol MFM 2021; 3:100481–100481.
22. Nir O, Schwartz A, Toussia-Cohen S, et al. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies between parturient women treated with the BNT162b2 messenger RNA vaccine during pregnancy. Am J Obstet Gynecol MFM 2022; 4:100492–100492.
23. Shaken LL, Atyeo CG, Yonker LM, et al. Durability of anti-spike antibodies in infants after maternal vaccination against COVID-19 or a natural infection. JAMA 2022; 327:1087–1089.
24. Mark KJ, Whitaker M, Agathis NT, et al. Hospitalization of infants and children aged 0-4 years with laboratory confirmed COVID-19 – COVID-NET, 14 states, March 2020-February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:429–436.
25. CV Hobbs, Woodworth K, Young CC, et al. Frequency, characteristics and complications of COVID-19 in hospitalized infants. Pediatr Infect Dis J 2022; 41 (3):and81–e86.
26. Mølgaard-Nielsen D, Fischer TK, Krause TG, Hviid A. Efficacy of maternal immunization with inactivated trivalent influenza vaccine in pregnant women and their children. J Intern Med 2019; 286:469–480.
27. Olson SM, Newham MM, Halasa NB, et al. Vaccine efficacy against life-threatening influenza disease in US children. Clin Infect Dis 2022 January 13 (Epub before print).
28. Chua H, Feng S, Lewnard JA, et al. The use of negative test controls to monitor vaccine efficacy: a systematic review of methodology. Epidemiology 2020; 31:43–64.
29. Olson SM, Newham MM, Halasa NB, et al. Efficacy of the BNT162b2 vaccine against critical Covid-19 in adolescents. N English J Med 2022; 386:713–723.
30. Olson SM, Newham MM, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA vaccination against hospitalization for COVID-19 among people aged 12-18 – US, June-September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1483–1488.
31. Federal Registry Office. Code of Federal Regulations: A point-in-time eCFR system. Title 45 (https://www.ecfr.gov/cgi-bin/text-idx?SID=fc043bd2812f0775fa80066558a6bbcf&mc=true&node=pt45.1.46&rgn=div5#se45.1.46_1102).
32. Razzaghi H., Meghani M, Pingali C, et al. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy – Eight Integrated Health Organizations, United States, December 14, 2020 – May 8, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:895–899.
33. Patel MK, Bergeri I, Bresee JS, et al. Evaluation of the efficacy of the post-introduction COVID-19 vaccine: summary of the provisional guidelines of the World Health Organization. Vaccine 2021; 39:4013–4024.
34. Centers for Disease Control and Prevention. COVID data tracker: proportions of variants (https://covid.cdc.gov/covid-data-tracker/#variant-proportions).
35. Gray KJ, Bordt EA, Atheist C., et al. Coronavirus Disease Vaccine Response 2019 in Pregnant and Lactating Women: A Cohort Study. Am J Obstet Gynecol 2021; 225 (3):303.e1–303.e17.
36. Klein NP, Stockwell MS, Demarco M, et al. Efficacy of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in the prevention of COVID-19-associated emergency wards and urgent care meetings and hospitalizations among non-immunocompromised children and adolescents aged 5-17 years – VISION Network, 10 States, April 2021 – January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:352–358.
37. Lauro AS, Tenforde MW, Chappell JD, et al. Clinical severity and efficacy of mRNA vaccines against Covid-19 from ommicron, delta and alpha variants SARS-CoV-2 in the United States: prospective observational study. Bmj 2022; 376:e069761–e069761.
38. Centers for Disease Control and Prevention. Cumulative archived data: Percentage of pregnant people aged 18 to 49 who received at least one dose of a COVID-19 vaccine during pregnancy in general, by race / ethnicity, and date reported to CDC-Vaccine Safety Datalink * , United States | December 20, 2020 – January 20, 2022 (https://data.cdc.gov/Vaccinations/Cumulative-Data-Percent-of-Pregnant-People-aged-18/4ht3-nbmd/data).
39. Nemet I, Kliker L, lust Y, et al. Third neutralization of the BNT162b2 vaccination of omicron SARS-CoV-2 infection. N English J Med 2022; 386:492–494.
40. Thompson MG, Natarajan K, Irving SA, et al. Efficacy of a Third Dose of mRNA Vaccines Against COVID-19 Associated Emergency and Emergency Care Meetings and Adult Admissions During Periods of Predominance of Delta and Omicron Variants – VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:139–145.